Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Public Advisory - Counterfeit Nuceiva injectable drug seized from New You Spa in Vaughan, Ontario


OTTAWA, ON, Sept. 6, 2022 /CNW/ - 

Summary

Counterfeit Nuceiva injectable drug seized from New You Spa in Vaughan, Ontario (CNW Group/Health Canada)

Counterfeit Nuceiva injectable drug seized from New You Spa in Vaughan, Ontario (CNW Group/Health Canada)

Counterfeit Nuceiva injectable drug seized from New You Spa in Vaughan, Ontario (CNW Group/Health Canada)

Counterfeit Nuceiva injectable drug seized from New You Spa in Vaughan, Ontario (CNW Group/Health Canada)

Counterfeit Nuceiva injectable drug seized from New You Spa in Vaughan, Ontario (CNW Group/Health Canada)

Affected products

Product

Strength

DIN

Lot

Expiry date

Counterfeit Nuceiva (Prabotulinumtoxin A) for injection

100 units/vial

02480158

121661

2023-04

Issue

Health Canada inspectors seized counterfeit Nuceiva (Prabotulinumtoxin A) from a New You Spa location in Vaughan, Ontario (Unit 5, 60 Winges Road). Nuceiva is botulinum toxin type A prescription drug that is administered by injection for the temporary improvement of facial wrinkling in adults 18 years of age and older.

Health Canada has confirmed with Evolus Inc., the manufacturer of Nuceiva, that the seized products are counterfeit. The counterfeit Nuceiva is labelled with lot 121661 and expiry 2023-04. Evolus Inc. confirmed there is an authorized lot with the same number; the lot expired in 2022-04. In addition, Evolus Inc. confirmed that:

Counterfeit drugs are made to look like authentic products, but they may not be the same and they can pose serious health risks. For example, they could contain a higher dosage than shown on the label, contaminants or hidden dangerous ingredients that can seriously harm your health. On the other hand, they might not contain the drug at all. Unlike authorized and authentic drug products, counterfeit drugs have not been assessed by Health Canada for safety, effectiveness and quality. Selling counterfeit health products in Canada is illegal.

Botulinum toxin type A is used for cosmetic purposes to treat facial wrinkling. Some products containing botulinum toxin type A are also used to treat severe muscle spasms in the neck, eye and foot, as well as chronic migraines, urinary incontinence, and excessive sweating. Authorized botulinum toxin type A products should only be used under specialist supervision and only if the benefits of treatment are considered to outweigh the risks. Potential risks associated with injecting an unauthorized Botulinum toxin type A product can range from mild local paralysis to death. In addition, unauthorized injectable health products for cosmetic purposes carry significant risk because of the potential for infection, scarring and poor outcomes. All products administered by injection in Canada must be authorized for sale by Health Canada.

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: